De novo design of protease-activatable cytokine prodrugs
Hojeong Shin, Julissa G. Tello, Chan Johng Kim, Jung-Ho Chun, Frank Peprah, Brendan D. Parent, Tavus Atajanova, Robiah Arefin Ibn Mahmud, Li Qiang, Andrew J. Aguirre, Stephanie K. Dougan, Michael Lawrence Dougan, David A. Baker
This study designs protease-activatable cytokine prodrugs to reduce toxicity while maintaining antitumor efficacy in tumor models.
bioRxiv · Sep 22, 2026 · PreprintBioengineering